	US 12,258,371 B2
	Stabilized immunoglobulin domains
Laura Deak Codarri, Schlieren (CH); Stefan Dengl, Penzberg (DE); Jens Fischer, Penzberg (DE); Thomas Hofer, Schlieren (CH); Laurent Lariviere, Penzberg (DE); Ekkehard Moessner, Schlieren (CH); Stefan Seeber, Penzberg (DE); Pablo Umana, Schlieren (CH); and Anne-Claire Zagdoun, Schlieren (CH)
Assigned to Hoffman-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Jul. 30, 2020, as Appl. No. 16/943,067.
Application 16/943,067 is a continuation of application No. PCT/EP2019/052162, filed on Jan. 30, 2019.
Claims priority of application No. 18154316 (EP), filed on Jan. 31, 2018.
Prior Publication US 2021/0054021 A1, Feb. 25, 2021
Int. Cl. C07K 16/28 (2006.01); C07K 1/04 (2006.01); C07K 16/30 (2006.01); C07K 16/40 (2006.01)

CPC C07K 1/047 (2013.01) [C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2881 (2013.01); C07K 16/3007 (2013.01); C07K 16/3053 (2013.01); C07K 16/40 (2013.01); C07K 2317/21 (2013.01); C07K 2317/56 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

10 Claims

1. An autonomous VH domain with cysteines in positions (i) 52a and 71 or (ii) 33 and 52 according to Kabat numbering, wherein said cysteines form a disulfide bond under oxidative conditions, comprising a heavy chain variable domain framework comprising a

(a) FRI comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 207,

(b) FR2 comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 208,

(d) FR4 comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 210;

(a) FR1 comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 211,

(b) FR2 comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 208,

(d) FR4 comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 210.